BSP – Biological Signal Processing Ltd.

tower2BSP is dedicated to providing novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease.

Using proprietary signal processing technology,  BSP’s products perform analysis of the high-frequency QRS components for more sensitive and accurate results than conventional stress testing and recently, also for resting ECG tests. The short video below describes this exciting technology.

Integration of BSP’s innovative technology into our top-of-the-line stress ECG systems enables a unique solution providing superior diagnostic accuracy, while utilizing conventional stress testing protocols.

What’s New
Office of the Chief Scientist (OCS)
approves funding for continuing the
development of the Resting ECG
technology
BSP presented its study on continuous HyperQ monitoring at the 12th International Dead Sea Symposium (IDSS)
BSP receives notice of allowance
from the USPTO for a patent
regarding its signal processing
technology
BSP's latest patent covering
HyperQ for resting ECG receives
notice of allowance from USPTO
BSP and Schiller launch the
HyperQ Analyzer Rest at the ESC
congress in Amsterdam
BSP receives notice of allowance
from the USPTO for its patent on
identification of myocardial ischemia
Prof. Michael Eldar, MD joins BSP's
board of directors
BSP receives CE certificate for its
first product in the Resting ECG
product line
Office of the Chief Scientist (OCS)
approves funding for continuing the
development of the Resting ECG
technology
BSP and Schiller AG sign
a collaboration and licensing
agreement for the HyperQ
Stress and Rest platforms